Cytogen (US) begins OncoScint breast cancer trials
This article was originally published in Clinica
Executive Summary
Cytogen (US) has begun clinical trials of its OncoScint CR/OV imaging agent for use in pre-operative breast cancer staging. The only FDA-approved monoclonal antibody-based tumour imaging agent, OncoScint CR/OV is indicated for colorectal and ovarian cancer. The multi-centre breast cancer trial aims to confirm the agent's ability to detect axillary lymph node metastases. In a 20-patient study at the Italian National Cancer Institute in Milan, the agent had a sensitivity of 91% in detecting axillary lymph node involvement in mastectomy candidates.